Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - RNAi/siRNA
 More »

THIS KEYWORD IS SPONSORED BY:

  • Harnessing the Power of Kinase Inhibitors
    The assay development and high-throughput screening system at the European ScreeningPort, Hamburg, Germany. The ~600 kinases that make up the human kinome comprise a group of ...
    5-8-2013
  • Ascletis Obtains Chinese Rights to Janssen HIV Treatment
    Ascletis said today it obtained exclusive rights from Assent R&D Ireland to develop, manufacture, and commercialize the next-generation HIV protease inhibitor (PI) TMC310911 in ...
    4-30-2013
  • Advances in RNAi Tools and Technologies
    RNAi research has capitalized on the ability to design and deliver small interfering RNAs (siRNAs) or short hairpin RNAs (shRNAs) to knock down expression of target genes with ...
    4-15-2013
  • Literature Review: Protein—Now You See It, Now You Don't
    Researchers describe a system for the rapid and complete degradation of proteins in mammalian cells. Figures 1A–B. Auxin-inducible degradation system for controlling protein ...
    3-7-2013
  • Transporter Knockout Cell Lines
    Sigma-Aldrich 3050 Spruce St. UNITED STATES MO 63103 Sigma-Aldrich is a leading Life Science and High Technology company. Our chemical and biochemical products and kits are used in ...
    3-1-2013
  • FLIGHT
    Do you work with Drosophila ? Are you planning any RNAi experiments? If you answered "yes" to those questions, then I have a website that may really help your project take ...
    2-15-2013
  • Alnylam Losses Widened by Tekmira Settlement
    Alnylam Pharmaceuticals finished the fourth quarter and all of 2012 in the red, hurt by a one-time $65 million charge to settle nearly two years of lawsuits vs. Tekmira ...
    2-8-2013
  • Cholesterol Drug Deal Worth Up to $205M
    The Medicines Company will develop and commercialize for Alnylam Pharmaceuticals a series of its RNA interference (RNAi) therapeutics targeting proprotein convertase subtilisin/...
    2-4-2013
  • James Watson Hypothesis Links Cancer to Antioxidants
    In a paper he called "among my most important work since the double helix," James D. Watson. Ph.D., posited a theory that links cancer progression in late stages of the disease to ...
    1-9-2013
  • Costly Cats: Dispelling Allergies-to-Animals Mythology
    The solution likely lies in controlling complex immune reactions rather than creating hypoallergenic pets. If you are even thinking of getting a nonallergenic pet for your allergic ...
    12-12-2012
  • Overcoming Drawbacks of Gene Silencing with RNAi
    Tools for Effective Validation and Utilization Gene silencing by RNA interference has become a key tool in research and drug discovery since its discovery by Andrew Fire and Craig ...
    12-1-2012
  • Screen Reveals Hundreds of Potential HD Targets
    A research team has identified hundreds of potential molecular targets linked to toxicity associated with Huntington's disease (HD), hoping that some of them may lead to new ...
    11-30-2012
  • Tekmira Gains License to an RNAi Technology
    Tekmira Pharmaceuticals said today it obtained a worldwide, nonexclusive license to Marina Biotech's Unlocked Nucleobase Analog (UNA) RNAi payload technology for development of ...
    11-29-2012
  • Burying the Hatchet: Alnylam Settles Tekmira RNAi Suits
    Alnylam settled nearly two years of lawsuits over lipid nanoparticle (LNP) technology for RNAi therapeutics by agreeing to pay Tekmira at least $65 million, and possibly $10 ...
    11-13-2012
  • Lucky 13 Serial Entrepreneurs
    Meet the most enterprising people in biotech. Any business owner will tell you that it takes a lot of wits, energy, know-how, and no shortage of luck to found your own company. ...
    11-12-2012
  • More »

    Journal Articles

  • Six-Transmembrane Epithelial Antigen of the Prostate (STEAP1...
    Rasilaben J. Vaghjiani, Sonia Talma, Christopher L. Murphy
    Tissue Engineering, Part A
    Six-Transmembrane Epithelial Antigen of the Prostate (STEAP1 and STEAP2)-Differentially Expressed by Murine and Human Mesenchymal Stem Cells Tissue Engineering, Part A Mesenchymal ...
  • RNA Memory Model: A RNA-Mediated Transcriptional Activation Mechanism...
    Walter Arancio
    Rejuvenation Research
    RNA Memory Model: A RNA-Mediated Transcriptional Activation Mechanism Involved in Cell Identity Rejuvenation Research Abstract I propose a new model, called the "RNA memory" model, ...
  • Human Osteoblast-Derived Factors Induce Early Osteogenic Markers...
    Matthias Ilmer, Marisa Karow, Claudia Geissler, Marianne Jochum, Peter Neth
    Tissue Engineering, Part A
    Human Osteoblast-Derived Factors Induce Early Osteogenic Markers in Human Mesenchymal Stem Cells Tissue Engineering, Part A The capacity of human mesenchymal stem cells (hMSC) for ...
  • PUMILIO-2 Is Involved in the Positive Regulation of Cellular...
    Patrícia Shigunov, Jose Sotelo-Silveira, Crisciele Kuligovski, Alessandra Melo de Aguiar, Carmen K. Rebelatto, José A. Moutinho, Paulo S. Brofman, Marco A. Krieger, Samuel Goldenberg, David Munroe, Alejandro Correa, Bruno Dallagiovanna
    Stem Cells and Development
    PUMILIO-2 Is Involved in the Positive Regulation of Cellular Proliferation in Human Adipose-Derived Stem Cells Stem Cells and Development Stem cells can either differentiate into ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll